Literature DB >> 8574343

Late onset hepatic failure due to hepatitis B virus with mutations in the pre-core region.

K Takase1, Y Oohashi, T Kihira, H Aonuma, M Hamada, T Nakano, Y Tameda.   

Abstract

A 60-year-old man complained of severe general fatigue on October 11, 1992. Pertinent laboratory findings were: aspantate aminotransferase (AST) 1920 IU, alanine aminotransferase (ALT) 2050 IU, and total bilirubin (T. Bil) 124 micromol/l (normal range, 0-17 micromol/l). Virological assay revealed that hepatitis B surface antigen (HBsAg), anti-hepatitis B e (HBe), anti-HBc, and immunoglobulin M (IgM) anti-HBc were positive, and anti-HBs, HBeAg, and anti-delta antibody were negative. A diagnosis of acute hepatitis due to hepatitis B virus was made. Despite a decrease in transaminase, jaundice worsened and prothrombin time was prolonged. On the 60th day of hospitalization, massive ascites developed, but the patient's consciousness was not impaired. Although, albumin and diuretics were given, the ascites further increased. Paracentesis of 2000 ml of ascitic fluid was performed twice a week. On the 120th day of hospitalization, the patient passed black stools and he exhibited renal failure 3 weeks later. Although severe jaundice persisted, he was still alert. On the 150th day of hospitalization, massive gastrointestinal bleeding occurred, due to hemorrhagic gastritis. Despite receiving intensive care, the patient died. Determination of the HBV DNA sequence revealed two point mutations in the pre-core region; these have not been reported elsewhere.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8574343     DOI: 10.1007/bf02367797

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  12 in total

1.  Fulminant hepatitis B: induction by hepatitis B virus mutants defective in the precore region and incapable of encoding e antigen.

Authors:  Y Kosaka; K Takase; M Kojima; M Shimizu; K Inoue; M Yoshiba; S Tanaka; Y Akahane; H Okamoto; F Tsuda
Journal:  Gastroenterology       Date:  1991-04       Impact factor: 22.682

2.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

3.  Late onset hepatic failure: clinical, serological and histological features.

Authors:  A E Gimson; J O'Grady; R J Ede; B Portmann; R Williams
Journal:  Hepatology       Date:  1986 Mar-Apr       Impact factor: 17.425

Review 4.  Acute hepatic necrosis and fulminant hepatic failure.

Authors:  B Rueff; J P Benhamou
Journal:  Gut       Date:  1973-10       Impact factor: 23.059

Review 5.  Fulminant and subfulminant liver failure: definitions and causes.

Authors:  J Bernuau; B Rueff; J P Benhamou
Journal:  Semin Liver Dis       Date:  1986-05       Impact factor: 6.115

6.  The complete nucleotide sequence of a pre-core mutant of hepatitis B virus implicated in fulminant hepatitis and its biological characterization in chimpanzees.

Authors:  N Ogata; R H Miller; K G Ishak; R H Purcell
Journal:  Virology       Date:  1993-05       Impact factor: 3.616

Review 7.  Difficult management problems in fulminant hepatic failure.

Authors:  S J Muñoz
Journal:  Semin Liver Dis       Date:  1993-11       Impact factor: 6.115

8.  Detection of hepatitis B pre-core mutant by allele specific polymerase chain reaction.

Authors:  E S Lo; Y M Lo; C H Tse; K A Fleming
Journal:  J Clin Pathol       Date:  1992-08       Impact factor: 3.411

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen.

Authors:  H Okamoto; S Yotsumoto; Y Akahane; T Yamanaka; Y Miyazaki; Y Sugai; F Tsuda; T Tanaka; Y Miyakawa; M Mayumi
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.